Vanguard Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$34.6M Sell
2,256,245
-8,001
-0.4% -$147K ﹤0.01% 2091
2026
Q2
$41.8M Buy
2,264,246
+1,544,552
+215% +$24.4M ﹤0.01% 2045
2026
Q1
$10.7M Buy
+719,694
New +$11.3M ﹤0.01% 2694

Other funds holding AVTX

Vanguard Capital Management's AVTX Position: Q3 2026 in Review

Vanguard Capital Management reduced its Avalo Therapeutics (AVTX) stake by 0.35% in Q3 2026, selling an estimated $147K and leaving 2,256,245 shares worth $34.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

Vanguard Capital Management first reported a position in AVTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $41.8M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Vanguard Capital Management held 2,256,245 shares of Avalo Therapeutics worth $34.6M as of Q3 2026.
  • Vanguard Capital Management sold 8,001 Avalo Therapeutics shares in Q3 2026, an estimated $147K.
  • Avalo Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2091 holding.
  • Vanguard Capital Management first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Avalo Therapeutics position peaked at $41.8M in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.